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ABSTRACT
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is one of the major pathogens in Iran
with a high prevalence and a high level of antibiotic resistance. Ceftaroline is a fifth generation ceph-
alosporin binding and inhibiting penicillin binding protein (PBP2a). Methods: In the present study, 228
clinical MRSA isolates were collected from four cities of Iran and their susceptibility to ceftaroline was
evaluated by E-test and the disk diffusion method. Results: Our results showed a high susceptibility rate
(97.3%) to ceftaroline in MRSA strains from Iran. Six isolates were found to be ceftaroline non-sus-
ceptible (CPT-NS) with Minimum inhibitory concentration (MIC) ≥2 mg/mL. All CPT-NS isolates were
isolated from blood and tracheal aspirate and belonged to SCCmec type III as well as agr type I and were
all susceptible to vancomycin. Out of six isolates, three, two and one belonged to spa type t030, t4864,
and t969, respectively. Vancomycin, quinupristin/dalfopristin, linezolid, chloramphenicol, and tigecy-
cline were the most active agents against CPT-NS isolates. Conclusion: Due to the broad-spectrum
activity and low toxicity of ceftaroline as well as the increased rate of vancomycin resistance among
MRSA strains in recent years, ceftaroline can be considered as a novel approach to treat MRSA-induced
infections.
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INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most important bacterial
pathogens worldwide, causing a number of community-acquired and health care-associated
infections, including septicemia, skin and soft tissue infections, osteomyelitis, and endo-
carditis [1]. The mean prevalence of MRSA in Iran is between 57.2 and 93.3 percent [2].
Antibiotic misuse has led to high resistance levels in MRSA strains leading to an increased
mortality rate, high costs of care and treatment, and longer hospitalization periods [3]. The
mechanism of resistance in MRSA is attributed to the presence of the mecA gene and the
subsequent expression of penicillin binding protein 2a (PBP2a) which confers low affinity to
common b-lactam antibiotics and hence, mediates resistance. Owing to high resistance rates
to different antibiotics, treatment of MRSA infections has become challenging, necessitating
the development of novel therapeutics [4]. Ceftaroline is a member of the fifth generation
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cephalosporins approved by the US Food and Drug
Administration (FDA) for the treatment of adults with
community-acquired bacterial pneumonia (CABP) as well as
acute bacterial skin and skin structure infections (ABSSSI).
There are also reports on the efficacy of this antibiotic for
the treatment of other infections, such as osteomyelitis and
epidural abscesses [5–7]. Furthermore, previous studies
have shown the efficiency of this antibiotic against methi-
cillin-susceptible S. aureus (MSSA), MRSA, and Strepto-
coccus pneumoniae [8, 9]. This antibiotic is probably also
efficient against other pathogens including Streptococcus
pyogenes, Haemophilus influenzae, Moraxella catarrhalis
and non-extended-spectrum b-lactamase-producing Enter-
obacteriales. Ceftaroline is notably the first cephalosporin
with a unique feature of high affinity to penicillin binding
protein 2a (PBP2a) with 800- and 1,400-fold lower half-
maximal inhibitory concentration for PBP2a compared to
oxacillin and ceftriaxone, respectively, making it a suitable
choice for the treatment of MRSA infections [10–13].
Therefore, due to the efficiency of ceftaroline in previous
studies, its fewer side effects, and the increased prevalence of
vancomycin-resistant S. aureus (VRSA) in recent years [14],
the aim of this study was to determine the frequency of
ceftaroline-resistance in MRSA strains collected from
different cities of Iran.
MATERIALS AND METHODS
Bacterial isolates
A total of 228 MRSA isolates were used in this study isolated
from blood (37.2%), tracheal aspirate (21.8%), wound
(18.2%), nasal swabs (6.9%), hospital surfaces (6.2%), ab-
scess (4.3%) skin lesion (1.7%), catheter (1.4%), and bone
aspiration (1.3%) were collected from hospitals in four cities
in Iran (including Tehran, Karaj, Yasuj, and Arak) between
2015 and 2018. The isolates were identified at the species
level by biochemical tests and Polymerase chain reaction
(PCR) amplification of the S. aureus-specific nucA gene was
performed as the confirmatory test [2, 3, 15, 16].
Antimicrobial susceptibility testing
The Liofilchem E-test strips (Roseto degli Abruzzi, Italy) as
well as the Mast (Liverpool, UK) and BD (New Jersey, USA)
antibiotic susceptibility discs were used for the determina-
tion of susceptibility profiles. Susceptibility to ceftaroline
was tested by a ceftaroline disc (30 mg) using the disk
diffusion method in accordance with the Clinical and Lab-
oratory Standards Institute (CLSI) guidelines [15]. Suscep-
tibility to ceftaroline was confirmed by gradient diffusion
test (E-test) and the results were interpreted according to the
CLSI and European Committee on Antimicrobial Suscepti-
bility Testing (EUCAST) guidelines [10, 17, 18]. Additional
antibiotic susceptibility testing for ceftaroline non-suscepti-
ble (CPT-NS) strains was performed for the following an-
tibiotics: nitrofurantoin (300 mg), gentamicin (10 mg),
rifampicin (5 mg), norfloxacin (10 mg), tigecycline (15 mg),
trimethoprim/sulfamethoxazole (25 mg), chloramphenicol
(30 mg), cefixime (5 mg), erythromycin (15 mg), clindamycin
(2 mg), tetracycline (30 mg), penicillin G (10 U), linezolid (30
mg), cefepime (30 mg), quinupristin/dalfopristin (15 mg)
ciprofloxacin (5 mg), and imipenem (10 mg) [19]. E-test
gradient diffusion test was also performed for the determi-
nation of vancomycin resistance.
DNA extraction and molecular typing of MRSA strains
DNA extraction was performed by the boiling method using
TE buffer (10 mMTris, 1 mM EDTA [pH 8.0]) as previously
described [20]. Identification of MRSA strains was per-
formed by the detection of mecA using PCR.
spa typing
The spa gene was amplified using the method described by
Harmsen et al. [21]. Amplicons were sent to Bioneer Co.
(Seoul, South Korea) for DNA sequencing. Data were
analyzed using the Ridom SpaServer database to determine
the Spa type of each isolate (http://www.spaserver.ridom.de)
[15, 16].
SCCmec typing
To determine the SCCmec types, a multiplex-PCR with four
pairs of primers was performed according to the method
described by Boye et al. [22, 23]. Each reaction contained
0.5mM of each primer and the final volume was 25 mL.
Finally, the PCR products were visualized by electrophoresis
on 1% agarose gels containing safe stain (Kawsar Biotech
Company, Iran) [15].
agr typing
To determine the agr types, PCR was performed as described
by Shopsin et al. [24]. In brief, agr types (I–IV) were
determined by multiplex PCR using the agr-specific primers.
Each agr type was analyzed in each strain after visualization
on 1% agarose gels containing safe stain [15].
RESULTS
Two hundred out of 228 strains [Tehran (95%), Yasuj (94%),
Karaj (75%) and Arak (77%)] were ceftaroline susceptible
upon disk diffusion. The Ceftaroline E-test strip was used to
determine the MIC values on 28 strains were non-suscep-
tible upon disk diffusion and according to the results, six
isolates showed an MIC of 2 mg/mL, including five isolates
from Arak and one from Tehran (Fig. 1). These six isolates
showed additional resistance to penicillin G, norfloxacin,
gentamicin, erythromycin, cefepime, cefixime, ciprofloxacin,
tetracycline, and imipenem and high resistance to clinda-
mycin (83.33, n 5 5) and rifampicin (83.33, n 5 5)
(Table 1). On the other hand, all CPT-NS isolates were
susceptible to vancomycin, quinupristin/dalfopristin, line-
zolid, chloramphenicol, and tigecycline. The most frequent
spa type was t030 (50%, n 5 3), followed by t4864 (33.3%, n
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5 2), and t969 (16.6%, n 5 1). Moreover, all six isolates
belonged to agr type I (100%, n 5 6) and SCCmec type III
(100%, n 5 6) (Table 2).
DISCUSSION
S.aureus infections are one of the major problems around
the world. In Iran, vancomycin has been frequently used to
treat complex infections caused by S. aureus, but in recent
years, resistance to this antibiotic has been reported,
necessitating novel therapeutic antibiotics [25–27]. We
collected 228 MRSA from four different Iranian cities to
evaluate the performance of ceftaroline against this path-
ogen. In a study by Dehkordi et al. on antibiotic resistance
pattern of the MRSA isolated from hospital food, among
485 isolates, all of them were resistant to ceftaroline [28].
In addition, in another study on phenotypic and genotypic
characterization of antibiotic resistance in the MRSA
strains isolated from hospital cockroaches, all isolates
recovered from external washing samples and gut content
samples were resistance to ceftaroline [29]. Despite two
previous studies from Iran in non-clinical samples, ac-
cording to our research, this is the first report from Iran to
evaluate the sensitivity of clinical MRSA isolates to cef-
taroline. The results of the present study showed that
97.3% (222/228) of the MRSA isolates showed suscepti-
bility to ceftaroline, while six isolates were non-suscepti-
ble. According to CLSI guideline, the susceptible dose
dependent (SDD) range of ceftaroline is between 2 and 4
mg/mL, meanwhile EUCAST consider 2 mg/mL as resis-
tance [17, 18]. In this study, ceftaroline MIC 2 mg/mL
considered as non-susceptible. All six isolates were highly
resistant to other beta-lactams, gentamicin, erythromycin,
ciprofloxacin, norfloxacin, and tetracycline. on the other
hand, they were completely inhibited by linezolid, vanco-
mycin, quinupristin/dalfopristin, and tigecycline which is
similar to other studies from Iran [2, 30]. In a study per-
formed on 8037 S. aureus, four isolates were reported as
CPT-NS strains which were susceptible to linezolid and
vancomycin, and belonged to SCCmec types III [31]. In a
study from Switzerland, 24% (23/96) of MRSA collected
from deep infections, blood cultures, and superficial in-
fections with MIC≥ 2 mg/L were reported as CPT-NS [32].
In the Atlas program, in which the ceftaroline suscepti-
bility of S. aureus isolates from different countries was
tested, 93.7% of the isolates were susceptible to this anti-
biotic, 5.9% were susceptible-dose dependent (SDD) and
only 0.4% (263/61,045) were found to be resistant. Among
Fig. 1. Results of Ceftaroline susceptibility testing by gradient diffusion test among MRSA isolates
Table 1. Antibiotic susceptibility pattern of the ceftaroline-




Cefepime 0 (0%) 0 (0%) 6 (100%)
Cefixime 0 (0%) 0 (0%) 6 (100%)
Chloramphenicol 6 (100%) 0 (0%) 0 (0%)
Ciprofloxacin 0 (0%) 0 (0%) 6 (100%)
Clindamycin 1 (16.7%) 0 (0%) 5 (83.3%)
Erythromycin 0 (0%) 0 (0%) 6 (100%)
Gentamicin 0 (0%) 0 (0%) 6 (100%)
Imipenem 0 (0%) 0 (0%) 6 (100%)
Linezolid 6 (100%) 0 (0%) 0 (0%)
Nitrofurantoin 1 (16.7%) 5 (83.3%) 0 (0%)
Norfloxacin 0 (0%) 0 (0%) 6 (100%)
Penicillin G 0 (0%) 0 (0%) 6 (100%)
Quinupristin/
Dalfopristin
6 (100%) 0 (0%) 0 (0%)
Rifampicin 1 (16.7%) 0 (0%) 5 (83.3%)
Tetracycline 0 (0%) 0 (0%) 6 (100%)
Tigecycline 6 (100%) 0 (0%) 0 (0%)
Trimethoprim/
Sulfamethoxazole
5 (83.3%) 0 (0%) 1 (16.7%)
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the resistant strains, 92% (242/263) were from Asia and
similar to our results, all bacterial isolates were susceptible
to vancomycin and linezolid and the highest resistance
rate was reported to clindamycin, erythromycin, and
gentamicin. Apparently, the rate of resistance to ceftaro-
line, gentamicin, clindamycin, and minocycline among
MRSA isolates was much higher in the Asia-Pacific region
compared to other parts of the world [33]. According to a
study performed by Pfaller et al. including 1732 commu-
nity-acquired MRSA isolates from the United States, only
3.1% were CPT-NS and all these isolates were susceptible
to vancomycin, linezolid, and tigecycline [1]. Moreover,
the results of another study showed that 100% non-
duplicate MRSA isolated from different samples of hos-
pitalized patients, were susceptible to ceftaroline, while
63% were resistant to gentamicin, erythromycin, clinda-
mycin, and ciprofloxacin and 15% were resistant to van-
comycin [34]. Finally, Sader et al. reported that all 523
studied S. aureus were susceptible to ceftaroline, and this
antibiotic could be used as surgical prophylaxis that would
cover all MRSA infections [35].
Our CPT-NS strains had agr types I and SCCmec types
III which has been related to hospital-acquired infection and
has been reported as the main SCCmec type in Iran with a
prevalence between 45% and 76% [2]. Half of these non-
susceptible isolates were obtained from Arak city and
characterized with spa type t030 which is one of the most
common spa types in Iran and seemingly most of them
reported to be member of ST239-CC8. To date, this clone is
spreading in several countries across Asia [2, 36]. Moreover,
in study on susceptibility to ceftaroline and molecular
epidemiology of MRSA isolates in China, results revealed
that the 95.2% of CPT-NS isolates were belong to CC8.
Additionally, the CPT-NS CC8 isolates were largely ST239-
III-t030 and ST239-III-t037 [37]. The results of a systematic
review which evaluated the clinical outcomes and side effects
of ceftaroline showed that this antibiotic improves the
treatment of severe MRSA infections [38]. In addition, drug
toxicity was infrequent and was only observed in case of
long-term use, and evaluation of blood parameters is rec-
ommended [38]. Therefore, due to high efficacy and low
toxicity of ceftaroline, recently increased vancomycin resis-
tance, high cost of linezolid and unavailability of daptomy-
cin in Iran, ceftaroline may be considered as a suitable
alternative to treat MRSA-induced infections. However,
given the varying degrees of resistance in different areas, it is
suggested to perform more comprehensive studies to fully
investigate the mechanism and frequency of ceftaroline
nonsusceptibility in MRSA strains.
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Table 2. Resistance patterns
Isolate Source Specimen spa SCCmec agr Vancomycin MIC Resistance Pattern
B123 Tehran Blood t4864 III I 1 NOR, IMI, T, GM, CIP, CFM, FEP, E,
TS, PG
Ar33 Arak Blood t030 III I 0.75 NOR, RIF, CD, IMI, T, GM, CIP, CFM,
FEP, E, PG
Ar44 Arak Blood t4864 III I 0.75 NOR, RIF, CD, IMI, T, GM, CIP, CFM,
FEP, E, PG
Ar59 Arak Tracheal aspirate t030 III I 1 NOR, RIF, CD, IMI, T, GM, CIP, CFM,
FEP, E, PG
Ar61 Arak Blood t030 III I 0.75 NOR, RIF, CD, IMI, T, GM, CIP, CFM,
FEP, E, PG
Ar72 Arak Tracheal aspirate t969 III I 0.75 NOR, RIF, CD, IMI, T, GM, CIP, CFM,
FEP, E, PG
NOR: Norfloxacin. IMI: Imipenem. T: Tetracycline. GM: Gentamicin. CIP: Ciprofloxacin. CFM: Cefixime. FEP: Cefepime. E: Erythromycin.
TS: Trimethoprim/Sulfamethoxazole. PG: Penicillin G. RIF: Rifampicin. CD: Clindamycin.
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